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Abstract
Comparative genomic hybridization (CGH) was used to
screen colorectal carcinomas for chromosomal aber-
rations that are associated with metastatic phenotype.
In total, 63 tumor specimens from 40 patients were
investigated, comprising 30 primary tumors, 22 sys-
temic metastases (12 liver, 6 brain, and 4 abdominal
wall metastases) and 11 lymph node tumors. Using
statistical analysis and histograms to evaluate the
chromosomal imbalances, overrepresentations were
detected most frequently at 20q11.2–20q13.2, 7q11.1–
7q12, 13q11.2 –13q14, 16p12, 19p13, 9q34, and
19q13.1 – 19q13.2. Deletions were prominent at
18q12–18q23, 4q27–4q28, 4p14, 5q21, 1p21–1p22,
21q21, 6q16–6q21, 3p12, 8p22–8p23, 9p21, 11q22,
and 14q13–14q21. Hematogenous metastases showed
more alterations than lymph node tumors, particularly
more deletions at 1p, 3, 4, 5q, 10q, 14, and 21q21 and
gains at 1q, 7p, 12qter, 13, 16, and 22q. Comparing liver
metastases with their corresponding primary tumors,
particularly deletions at 2q, 5q, 8p, 9p, 10q, and 21q21
and gains at 1q, 11, 12qter, 17q12–q21, 19, and 22q
were more often observed. The analysis suggested
that the different pathways of tumor dissemination are
reflected by a nonrandom accumulation of chromoso-
mal alterations with specific changes being respon-
sible for the different characteristics of the metastatic
phenotype.
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Introduction
Cancer of the colon and rectum is the second most preva-
lent cause of cancer deaths in men and the third most
common in women [1]. Metastasis is responsible for most
cancer deaths. It represents the essential step during can-
cer progression from a locally growing tumor to a metastatic
killer. This switch is believed to involve numerous alterations
that allow tumor cells to complete the complex series of
events needed for metastasis. Relatively few genes have
been implicated in these events. Therapeutic strategies to
prevent the development of metastases thus have potential
impact on cancer mortality. The development of these thera-
pies requires a better understanding of the biology and molec-
ular events of the metastatic process. Therefore, a primary goal
in our research is the understanding of the molecular mecha-
nism mediating not only the development of primary colorectal
cancers but also the process of colon carcinoma metastasis.
Metastasis is defined as the spread of cells from a primary
neoplasm to distant secondary sites and proliferation at these
sites. This highly selective process consists of a series of
linked, sequential steps favoring the survival of a subpopulation
of metastatic cells that preexist within the primary tumor mass
[2]. These steps include the detachment of cells from the
primary tumor, invasion of the surrounding tissues, penetration
into the circulation (bloodstream or lymphatic system), implan-
tation into the capillary beds of target organs, extravasation and
invasion into the target tissue, formation of vascular network,
and, finally, proliferation at this secondary site of implantation
[2,3]. For production of clinically or microscopically detectable
metastases, each of these steps must be completed. Failure
to complete even one step in this process (e.g., the inability to
invade host stroma, a high degree of antigenicity, inability to
grow in a distant organ’s parenchyma) results in tumor cell
elimination or dormancy. The successful metastatic cell must,
therefore, exhibit a complex phenotype that experimental evi-
dence suggests to be regulated by transient or permanent
changes in different genes at the DNA and mRNA level(s)
[3]. Numerous examples exist in which malignant tumors
metastasize to specific organs. Paget [4] proposed in 1889
that the organ microenvironment (the soil) can influence the
implantation, invasion, survival, and growth of particular tumor
cells (the seeds). This hypothesis explains colonization pat-
terns that cannot be explained solely by mechanical lodgment
theories and anatomical considerations [5].
Abbreviation: CGH, comparative genomic hybridization
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Recently, we hypothesized that distinct chromosomal
alterations of the primary tumors may predispose to dissem-
ination and may thus play a role in the early phase of
metastasis formation (metastasis initializer lesions), where-
as others are responsible for the peculiarities of the meta-
static phenotype-like organ-specific metastasis formation
and may be preferentially acquired during later phases
(metastasis modulator lesions) [6]. It is interesting to note
that many metastasis-associated lesions are detectable in
the primary tumor, questioning the model of a stepwise
cancer progression [7].
To provide cytogenetic data, we investigated 63 meta-
static colorectal carcinomas, 30 primary carcinomas, and 33
metastases from different sites by comparative genomic
hybridization. Using difference histograms and case-by-case
histograms for the analysis of paired tumor samples from the
same patient, we were able to identify recurrent novel
chromosomal changes in different metastatic sites.
Materials and Methods
Patients and Tumor Samples
The study consisted of 63 specimens from 40 patients,
which were mainly obtained during surgical resections at the
Department of Surgery of the Charite´ at Campus Buch.
Additionally, tumor specimens of the brain were collected
during neurosurgical operations at the Charite´ Hospital. The
tumor collective and its clinicopathological data according to
the TNM criteria of the UICC are summarized in Table 1.
Nineteen of 35 patients showed hematogenous and lymph
node metastases. Liver and nodal metastases were ob-
served in nine patients. In all brain metastases, the nodal
status was unknown and the four abdominal wall metastases
showed lymph node metastases in two patients, no lymph
nodemetastases in one patient, and unknown nodal status in
the other patient.
One aliquot of tumor tissues was frozen in liquid nitrogen
and kept at 80jC until DNA extraction. DNA was extracted
from several 30-mm cryostat tissue sections by proteinase K
digestion and phenol chloroform extraction, which was ver-
ified to consist of a minimum of 70% tumor cells in each case.
A second aliquot was submitted to formalin fixation and
paraffin embedding.
Comparative Genomic Hybridization (CGH)
DNA labelling, hybridization, and detection were per-
formed as previously described [6]. The protocols are also
available at our web site (http://amba.charite.de/cgh). DNA
was extracted from several 30-mm cryostat tissue sections by
proteinase K and phenol chloroform extraction, which was
verified to consist of a minimum of 70% tumor cells in
each case.
Digital Image Analysis
Image acquisition and digital image analyses have also
been described in detail [8]. At least 15 metaphases/karyo-
grams were analyzed per case, calculating CGH sum karyo-
grams and mean ratio profiles with confidence intervals.
Briefly, the deviations of the mean FITC/TRITC profiles from
the normal ratio of 1.0 were tested for significance by a two-
sided Student’s t-test. Deviations of the ratio profile with at
least 99% significance in the Student’s t-test were scored as
DNA gains or losses (i.e., only those imbalances in which the
ratio profile with its 99% confidence interval exceeded the line
of the normal ratio 1.0 to the same side were included in the
evaluation). This procedure is rather sensitive for scoring
chromosomal alterations by CGH [6,8]. Pronounced DNA
gains and losses of the tumor collective shown in the
histogram of Figure 1A were defined by those alterations
exceeding the ratio values 1.5 and 0.5, respectively.
They most likely correspond to high copy amplifications or
multicopy deletions.
Comparison of Tumor Subgroups (e.g., Lymph Node
Tumors and Liver Metastases)
A difference histogram (Figure 1B) was generated as
described to compare the lymph node tumors and liver
metastases as tumor subgroups [6]. Only alterations with
99% significance were included in this analysis. The per-
centage of changes occurring only in liver metastases is
represented by the red color, whereas the excess of changes
in the lymph node tumors is shown in green. The white areas
beneath the colored part of the histogram represent the
percentage of changes that are present in both subgroups.
A large colored area thus indicates a pronounced difference
between the tumor groups. The differences were tested for
significance by a chi-square test. Areas with 95% signifi-
cance (.01 < P < .05) are depicted in bright grey, and areas
with 99% significance (P < .01) are depicted in dark grey
horizontal lines.
In addition, we applied our newly developed case-by-case
histogram in this study. It visualizes the comparison of paired
samples (i.e., the primary tumor and its corresponding
metastasis). Within the histogram, the changes are differen-
tiated into four types [i.e., imbalances that are common in
both tumors (blue color), those that are present additionally
in the primary tumor (green), those that are present addi-
tionally in the metastasis (red), as well as no changes at all in
both groups] (Figure 1C, yellow).
Table 1. Tumor Collective.
Number of specimens 63
Number of patients 40
Primary tumors 30
Metastases 33
Liver 12
Lymph nodes 11
Brain 6
Abdominal wall 4
Dukes stage of patients
B 3
C 2
D* 35
*Nineteen of 35 patients with hematogenous spread (pM1) showed additional
lymph node metastases (5 pN0, 5 pN1, 14 pN2, 11 pNX; X = status
unknown).
24 Alterations During Lymphatic and Liver Metastasis Kno¨sel et al.
Neoplasia . Vol. 6, No. 1, 2004
Figure 1. (A) Summary of all genetic alterations of 63 advanced colorectal carcinomas in a histogram representation. The chromosomal imbalances are shown as
incidence curves along each chromosome. Areas on the left side of the chromosome ideogram correspond to loss of genetic material; those on the right side
correspond to DNA gains. The changes were determined by a statistical method. Those with 99% significance in the Student’s t-test are shown in blue; the
additional ones with only 95% significance are depicted in green. Pronounced DNA gains and losses, defined as regions where the ratio profile exceeded the fixed
thresholds 1.5 and 0.5, are shown in red and most likely correspond to high copy amplification and multicopy deletions, respectively. Heterochromatic areas
(centromeric and paracentromeric regions of chromosomes 1, 9, and 16; p arms of acrocentric chromosomes) must be excluded from the analysis. (B) Difference
histogram of lymph node metastases (n = 11) versus liver metastases (n = 12). The red areas represent the percentage of changes that are present only in liver
metastases, whereas the green color indicates the excess of changes of lymph node metastases. The white areas beneath the colored part of the histogram
represent the percentage of changes that are present in both tumor groups. The liver metastases (hematogenous) showed more alterations than lymph nodes
tumors (lymphogenous) with significant changes as indicated by the gray horizontal lines (light gray, regions with 95%; dark gray, regions with 99% significance;
chi-square test) (e.g., overrepresentation at 1q22–q23 and deletions at 4p). (C) Case-by-case histogram of 10 paired samples (i.e., primary tumor and
corresponding liver metastasis). Four conditions are represented: blue, percentage of chromosomal imbalances that are common in both tumors; green: those
chromosomal imbalances that are additionally seen in the primary tumor; red, those that are extra present in metastases; yellow, proportion with no changes in both
groups. The blue areas are dominating again, reflecting the high concordance between primary tumors and metastases. However, the metastases showed
additional alterations at several regions (e.g., gains at 1q and losses at 2q, 5q31, 8p, and 21q).
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Results
Histogram Analysis of All Colorectal Carcinomas and
Specific Subgroups
The chromosomal imbalances of the 63 colorectal carci-
nomas were first summarized by a histogram (Figure 1A). It
represents the DNA gains and losses as an incidence curve
along each chromosome. Additional histograms were calcu-
lated for the subgroups of primary tumors, lymph nodes, and
liver metastases. For the comparison of these groups, dif-
ference histograms (Figure 1B ) as well as case-by-case
histograms (Figure 1C ) were generated, which are exempli-
fied in Figure 1.
In general, regional (lymphogenous) metastases carried
less copy number aberrations than hematogenous metasta-
sis (Figure 1B). Only a few changes were more frequently
found in the lymph node tumors compared to the primary
tumors (i.e., deletions of chromosome 18 and 21q). In
contrast, many more alterations were seen in hematogenous
metastases (i.e., deletions at 1p, 3, 4, 5q, 10q, 14, and 21q
and gains at 1q, 7p, 12qter, 13, 16, and 22q). Comparing liver
metastases with their corresponding primary tumors, partic-
ularly deletions at 2q, 5q, 8p, 9p, 10q, 11p, and 21q and
gains at 1q, 11q, 12qter, 17q12–21, 19, and 22q were more
often observed. The compilation of data is presented
in Figure 2.
Discussion
This study is the first comprehensive and largest analysis of
DNA gains and losses associated with lymphatic and liver
metastasis formation of colorectal cancer. Investigating me-
tastasizing colorectal carcinoma resection specimens, we
were able to study 30 primary tumors and 33 metastases
by CGH. As a result, recurrent chromosomal regions in-
volved in the neoplastic progression of colorectal cancer
and their different dissemination pathways were detected.
The fact that we confirmed several changes that have been
previously reported using other methodologies supports the
validity of our findings. Furthermore, we analyzed tumor
pairs (i.e., primary versus metastatic carcinoma or lymph
node versus liver metastasis) from the same patient, which
is, in our opinion, an appropriate study design to identify
genetic alterations in metastasis.
The CGH data, together with typical morphological fig-
ures, were represented in the progression model of Figure 2.
It is important to note that there are often characteristic
morphologic differences between tumors at distinct sites.
Figure 2. Colorectal cancer progression model with typical morphological and chromosomal changes. Typical chromosomal imbalances associated with lymph
node and liver metastasis formation are represented, DNA gains are shown in red; DNA losses in green. The two arrows indicate that lymphatic and hematogenous
tumor spread may occur independently of each other, although there are alterations common for both dissemination pathways (e.g., deletions on 8p and 21q21).
Additionally, there are characteristic morphologic features. Liver metastases typically show a kribriform solid tumor growth with pronounced apoptosis and necrosis
with only little stroma, a pattern frequently detectable already in the primary tumor corresponding to a poorly differentiated carcinoma (G3, high-grade). In contrast,
lymph node metastasis and nonmetastasizing primary tumors often show a predominant tubular differentiation with a strong desmoplastic stroma reaction and are
thus classified as low-grade carcinomas (G1 and G2).
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Liver metastases typically show a kribriform solid tumor
growth with pronounced apoptosis and necrosis with only
little stroma, a pattern being frequently detectable already in
the primary tumor corresponding to a poorly differentiated
carcinoma (G3, high-grade). In contrast, lymph node metas-
tases and nonmetastasizing primary tumors often show a
predominant tubular differentiation with a strong desmoplas-
tic stroma reaction and are thus classified as low-grade
carcinomas (G1 and G2). These morphologic differences
are probably associated with the distinct biologic behavior.
Additionally, they may induce a technical bias (i.e., a more
prominent normal cell contamination in lymph node metasta-
sis and primary tumors compared to hematogenous metas-
tasis in parenchymal organs such as the liver). We checked
our fresh-frozen tumor samples in each specimen by hema-
toxylin and eosin (HE) staining and used macrodissection to
minimize the amount of contaminating normal tissue. Al-
though this may still influence the analysis, we are convinced
that the higher overall number of genomic alterations in the
liver metastases cannot be explained by these methodolog-
ical considerations. This is a confirmation of our previous
results indicating that additional alterations occur during
hematogenous dissemination, suggesting specific altera-
tions being responsible for dissemination to the brain [9].
Many of the specific chromosomal imbalances that we
identified (i.e., losses at 1p, 3p, 4, 5q, 10q, 14q, and 21q and
gains at 1q, 11, 12qter, 17q12–q21, 19, and 22q) have
already been associated with tumor progression and dis-
semination in colon cancer [6,10–12] or other cancer types
[9,13–21]. Similarly, many candidate genes were already
described (e.g., S100A4 and Cox-2 on 1q [22,23], BLU on 3p
[24], APC at 5q21 [25], c-erb-B2 at 17q21 [26], AIB1 at 20q
[14], and MMP11 at 22q12.2 [19]). In general, it is important
to note that the chromosome losses and gains may not only
be associated with the inactivation or activation of any
specific tumor suppressor gene or protooncogene, but cor-
respond to changes in the expression level of multiple genes,
which may directly or indirectly affect tumor growth and
dissemination. Furthermore, the chromosome regions may
harbor several classical tumor suppressor genes (e.g., p14,
p15, and p16 on chromosome 9p) [27,28].
Our data and the thereof derived model indicate that there
are independent pathways of colorectal tumor dissemination
and that these are associated with a nonrandom accumula-
tion of chromosomal alterations underlying the different
characteristics of the metastatic phenotype. It also highlights
two well-known pathogenetic mechanisms: 1) metastasis
formation may occur immediately after invasion of the pri-
mary tumor; and 2) hematogenous dissemination may occur
independently from lymphatic tumor spread. Obviously,
there is an overlap between the genetic alterations of the
tumor subgroups correlating with the fact that many tumors
develop both lymph node or hematogenous filiae. Lymphatic
spread, however, is not a prerequisite of systemic dissemi-
nation, which may occur early after cancer initiation. Accord-
ingly, there is probably no stepwise acquisition, but a
selection of tumor cell clones carrying the favorable metas-
tasis-associated lesions that are initially generated randomly
by the inherent chromosomal instability of most colorectal
carcinomas. In general, our model fits well with the alter-
ations described previously [6,9,12,29–33]. Similar to the
progression model of Fearon and Vogelstein [25] concen-
trating on genetic lesions, we would argue that the accumu-
lation of specific chromosomal imbalances, rather than their
order, is important for the progression of colorectal cancer.
In conclusion, the CGH data presented here define a set
of novel genomic regions in the human genome that are likely
to harbor genes that play an important role in the genesis of
organ-specific metastasis. Further molecular genetic studies
will identify more precisely these regions and will hopefully
lead to the identification of relevant genes underlying the
metastatic process.
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